Tvardi Therapeutics

📍 Houston, United States🗓 Founded 2017👥 20 employees💰 Last funded Apr 2021
Biotechnology Research🌐 tvardi.com
Website LinkedIn
Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians. Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions. Tvardi is conducting a first-in-human Phase Ia dose-escalating study to determine safety and dosing for follow-on studies for its lead compound, TTI-101. Collectively, the societal and economic impact of STAT3-dependent disease is significant. Tvardi is highly motivated to develop safe and effective small molecule inhibitors of STAT3 for use across numerous diseases.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Tvardi Therapeutics?
Tvardi Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Tvardi Therapeutics last raise funding?
The most recent investment in Tvardi Therapeutics recorded on gritt.io was in April 2021.
When was Tvardi Therapeutics founded?
Tvardi Therapeutics was founded in 2017.
What industry is Tvardi Therapeutics in?
Tvardi Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Tvardi Therapeutics based?
Tvardi Therapeutics is headquartered in Houston, United States.